Why Great Science Fails Without a Commercialization Strategy

The history of healthcare is full of brilliant science that never became a product anyone could use. The molecule worked, the data were strong, and still the company failed. This is not a paradox. It is the predictable result of treating science as the whole job when it is only the first part. This essay explains why great science fails without a commercialization strategy. It is educational and is not investment advice.

Science is necessary but not sufficient

A therapy that works is the price of entry, not the prize. Around that working therapy must be built a system that can manufacture it, win coverage, price it sustainably, reach prescribers, and survive the years and capital required to do all of that. Each of these is a discipline in its own right, and weakness in any one can sink a program no matter how strong the science. Founders who believe a good enough molecule will sell itself are repeating one of the oldest mistakes in the field.

The manufacturing trap

Many strong programs fail because they cannot make their product reliably at scale. A process that works in the lab may not survive scale-up, and for biologics the process is part of the product, making manufacturing a scientific challenge equal to the original discovery. This is why manufacturing capability is treated as a durable advantage rather than a logistics detail, as argued in the analysis of the manufacturing moat and the discussion of scaling from lab to market. A therapy that cannot be made cannot be sold.

The reimbursement trap

Even a therapy that is approved and manufacturable can fail if payers will not cover it at a sustainable price. In healthcare the patient is rarely the payer, so coverage is a second approval that many companies underestimate, as explained in the essay on the role of reimbursement. A company that generates the evidence regulators want but not the evidence payers need can clear approval and then find no viable market waiting for it.

The market-access trap

Reaching prescribers and patients requires an organization most research-stage companies do not have, including market access, distribution, and often a sales force. Building this is expensive and slow, which is why many biotechs choose to be acquired by larger companies that already have it. Failing to plan for this capability, and discovering at launch that the company can neither commercialize alone nor partner well, is a common way that good science stalls at the finish line.

The capital and timing trap

Commercialization takes money and time, and the base rates are humbling. Only a low double-digit percentage of drugs entering human testing reach approval, and the capitalized cost of those that succeed is enormous (Hay et al., 2014; DiMasi, Grabowski, and Hansen, 2016). A company that has not financed itself for the full journey, including the costly commercialization phase, can run out of money after the science succeeds but before the product reaches patients. Being right and broke is still a failure.

Why brilliant teams still fall into these traps

The traps persist because the people who excel at the science are often least experienced with the commercial realities, and because the incentives of early funding reward visible scientific milestones over invisible commercial groundwork. Each company also tends to believe its science is so compelling that the rest will follow, which is precisely the belief that leads to neglect. The antidote is to treat commercialization as a core strategic problem from the start, not a victory lap after approval.

The pattern Great science failing for commercial reasons is common and well documented. The failure is usually strategic, not scientific.

The takeaway

The uncomfortable truth is that the science is the part most likely to be done well and least likely, on its own, to determine success. A commercialization strategy that addresses manufacturing, reimbursement, market access, capital, and timing from early in development is what turns a discovery into a durable business. The full discipline is laid out in how to commercialize a biotech innovation, and the broader pattern of failure in why biotech startups fail. For how this judgment is applied in practice across decades of building healthcare companies, see the professional biography and the advisory practice.

Reframing what a biotech is actually building

Underneath these traps is a question of identity: what is a biotech company actually building? If the answer is a molecule, then science is the whole job and commercialization is someone else's problem. If the answer is a therapy that reaches patients and sustains a business, then science is one component of a much larger system, and commercialization is part of the core product from day one. The companies that succeed tend to hold the second view. They see manufacturing, reimbursement, and market access not as obstacles between their science and the world, but as integral parts of what they are creating. This reframing changes decisions early: which evidence to generate, which capabilities to build or partner for, how much capital to raise, and when. It also changes how a company tells its story to investors, who increasingly reward teams that demonstrate this fuller understanding. The shift from building a molecule to building a therapy that endures is the difference between science that stays in journals and science that changes care, a distinction explored from the science side in the cancer library's account of cancer treatment vs cancer research.

What investors learn to look for

Experienced healthcare investors have internalized these failures, which is why they probe commercialization readiness as hard as they probe the science. They ask how a therapy will be manufactured at scale, what the path to reimbursement looks like, who will sell it, and whether the company is financed for the full journey. A team that answers these questions crisply signals that it understands the real job, while a team that waves them away as details to handle later signals risk. For founders, the implication is that building commercialization capability is not only good operating practice but also a fundraising advantage, because it addresses exactly the concerns sophisticated investors carry from past disappointments. This is part of what separates an investable company from a merely interesting one, a distinction developed in what makes a biotech investable.